Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases

European Heart Journal

Volumn 26, Issue 16, 2005, Pages 1585-1595

  Jochmann, Nicoline ^a   Stangl, Karl ^a   Garbe, Edeltraut ^a   Baumann, Gert ^a   Stangl, Verena ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cardiovascular; Drugs; Gender; Pharmacokinetics; Therapy; Women

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CLOPIDOGREL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; ESTROGEN; FELODIPINE; GESTAGEN; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; PERINDOPRIL; PROPRANOLOL; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COUGHING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; EDEMA; ESTROGEN THERAPY; HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG QT SYNDROME; MEDLINE; META ANALYSIS; MORTALITY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW; TORSADE DES POINTES; URTICARIA; VASCULAR DISEASE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ASPIRIN; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIGITALIS GLYCOSIDES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; SEX FACTORS; TICLOPIDINE; WOMEN'S HEALTH;

EID: 25844458971     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi397     Document Type: Review

References (129)

1. Douglas PS. Gender, cardiology, and optimal medical care. Circulation 1986;74:917-919.
2. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 2000;343:475-480.
3. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics. Clin Pharmacokinet 2002;41:329-342.
4. Gross JL, Friedman R, Azevedo MJ, Silveiro SP, Pecis M. Effect of age and sex on glomerular filtration rate measured by 51Cr-EDTA. Braz J Med Biol Res 1992;25:129-134.
5. Conte MR. Gender differences in the neurohumoral control of the cardiovascular system. Ital Heart J 2003;4:367-370.
6. Legato M. Gender and the heart: sex-specific differences in normal anatomy and physiology. J Gend Specif Med 2000;3:15-18.
7. Burke JH, Goldberger JJ, Ehlert FA, Kruse JT, Parker MA, Kadish AH. Gender differences in heart rate before and after autonomic blockade: evidence against an intrinsic gender effect. Am J Med 1996;100:537-543.
8. Liu K, Ballew C, Jacobs DR Jr, Sidney S, Savage PJ, Dyer A, Hughes G, Blanton MM. Ethnic differences in blood pressure, pulse rate, and related characteristics in young adults. The CARDIA study. Hypertension 1989;14:218-226.
9. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353-370.
10. Villareal RP, Woodruff AL, Massumi A. Gender and cardiac arrhythmias. Tex Heart Inst J 2001;28:265-275.
11. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003;42:107-121.
12. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33-60.
13. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001;2:349-351.
14. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003;38:978-988.
15. Walle T, Walle UK, Cowart TD, Conradi EC. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 1989;46:257-263.
16. Hamelin BA, Desgagnés V, Rail J, Bogaty P, Morin J, Turgeon J. CYP2D6 ultrarapid metabolism and response to metoprolol. Pharmacotherapy 1997;17:1081.
17. Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34:203-218.
18. Labbé L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J, Hamelin BA. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000;10:425-438.
19. Fröhlich M, Albermann N, Sauer A, Walter-Sack I, Haefeli WE, Weiss J. In vitro and ex vivo evidence for modulation of p-glycoprotein activity by progestins. Biochem Pharmacol 2004;68:2409-2416.
20. Wilson K. Sex-related differences in drug disposition in men. Clin Pharmacokinet 1984;9:189-202.
21. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by p-glycoprotein. Clin Pharmacol Ther 2002;72:474-489.
22. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-491.
23. Hogstedt S, Lindberg B, Rane A. Increased oral clearance of metoprolol in pregnancy. Eur J Clin Pharmacol 1983;24:217-220.
24. Llerena A, Cobaleda J, Martinez C, Benitz J. Interethnic differences in drug metabolism: influence of genetic and environmental factors on desrisoquine hydroxylation phenotype. Eur J Drug Metabol Pharmacokinet 1996;21:129-138.
25. Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997;62:400-407.
26. 1-adrenoceptor upon ischemic insult in the rat heart. Pharmacol Exp Ther 2004;309:8-15.
27. 1-adrenergic receptors in ovariectomized rat hearts. Life Sci 2003;72:1813-1824.
28. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999;66:594-601.
29. Kendall MJ, Quarterman CP, Jack DB, Beeley L. Metoprolol pharmacokinetics and the oral contraceptive pill. Br J Clin Pharmacol 1982;14:120-122.
30. Walle T, Walle K, Mathur RS, Palesh YY, Conradi EC. Propranolol metabolism in normal subjects: association with steroid hormones. Clin Pharmacol Ther 1994;56:127-132.
31. Gilmore DA, Gal J, Gerber JG, Nies AS. Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 1992;261:1181-1186.
32. Walle T, Byington RP, Furberg CD, McIntyre KM, Vokonas PS. Biologic determinants of propranolol disposition: results from 1308 patients in the beta-Blocker Heart Attack Trial. Clin Pharmacol Ther 1985;38:509-518.
33. The beta-Blocker Heart Attack Trial (BHAT). A randomized trial of propanolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-1714.
34. Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, Herlitz J, Hjalmarson A, Sonneblick EH. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992;13:28-32.
35. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
36. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-2199.
37. Tabassome S, Mary-Krause M, Funck-Brentano C, Jaillon P; on behalf of the CIBIS II Investigators. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001;103:375-380.
38. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in metoprolol extended-release randomized intervention trial in heart failure (MERIT-HF). Circulation 2002;105:1585-1591.
39. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002;53:672-677.
40. Harrison-Bernard LM, Schulman IH, Raij L. Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity. Hypertension 2003;42:1157-1163.
41. Harvey PJ, Morris BL, Miller JA, Floras JS. Estradiol induces discordant angiotensin and blood pressure responses to orthostasis in healthy post-menopausal women. Hypertension 2005;45:399-405.
42. Schunkert H, Danser AH, Hense HW, Derkx FH, Kurzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997;95:39-45.
43. Massana E, Barbanoj MJ, Moros C, Morte A, Gich I, Jane F. No sex-related pharmacokinetic and pharmacodynamic differences of captopril. Pharmacol Res 1997;36:41-47.
44. Saenz-Campos D, Bayes MC, Massana E, Martin S, Barbanoj M, Jane F. Sex-related pharmacokinetic and pharmacodynamic variations of lisinopril. Methods Find Exp Clin Pharmacol 1996;18:533-538.
45. Vree TB, Dammers E, Ulc I, Horkovics-Kovats S, Ryska M, Merkx I. Lack of male-female differences in disposition and esterase hydrolysis of ramipril to ramiprilat in healthy volunteers after a single oral dose. Scientific World J 2003;3:1332-1343.
46. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, Johnston CI, McNeil JJ, MacDonald GJ, Marley JE, Morgan TO, West MJ, for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-592.
47. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-1456.
48. Shekelle PG, Rich MW, Morton SC, Atkinson W, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner tevenson L. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. J Am Coll Cardiol 2003;41:1529-1538.
49. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E, for the ACE inhibitor myocardial infarction collaborative group. Long-term ACE inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-1581.
50. Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, Suhan P, Micks M, Probstfield J, Bernstein V, Yusuf S. Effect of long-term therapy with ramipiril in high-risk women. J Am Coll Cardiol 2002;40:693-702.
51. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
52. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068.
53. Pitt B. ACE inhibitors for patients with vascular disease without left ventricular dysfunction - may they rest in PEACE? N Engl J Med 2004;351:2115-2117.
54. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 1999;47:111-114.
55. Strocchi E, Malini PL, Valtancoli G, Ricci C, Bassein L, Ambrosioni E. Cough during treatment with angiotensin-converting enzyme inhibitors. Analysis of predisposing factors. Drug Invest 1992;4:69-72.
56. Pillans PI, Coulter DM, Black P. Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 1996;51:123-126.
57. Gleiter CH, Mörike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 2002;41:7-17.
58. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14:73-86.
59. Vachharajani NN, Shyu WC, Smith RA, Greene DS. The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol 1998;46:611-613.
60. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
61. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.
62. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
63. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
64. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Östergren J, Yusuf S; CHARM investigators and committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003;362:759-766.
65. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
66. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-760.
67. Physicians' Desk Reference 2005; editorial 59; www.pdr.net.
68. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone in morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
69. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
70. Kang D, Verotta D, Krecic-Shepard ME, Modi NB, Gupta SK, Schwartz JB. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. Clin Pharmacol Ther 2003;73:31-40.
71. Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther 2000;68:286-292.
72. Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR, Schwartz JB. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000;68:130-142.
73. Abad-Santos F, Novalbos J, Galvez-Mugica MA, Gallego-Sandin S, Almeida S, Vallee F, Garcia AG. Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharmacol Res 2005;51:445-452.
74. Schwartz JB, Capili H, Daugherty J. Aging of women alters s-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994;55:509-517.
75. Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M, for the Amlodipine Cardiovascular Community Trial Study Group. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1996;77:713-722.
76. Kjeldsen SE, Kolloch RE, Leonetti G, Malliond J-M, Zanchetti A, Elmfeldt D, Warnold I, Hansson L for the HOT Study Group. Influence of gender and age on the preventing cardiovascular disease by antihypertensive treatment and acetysalicyl acid. The HOT Study. J Hypertens 2000;18:629-642.
77. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
78. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-372.
79. Fagard RH, Staessen JA, Thijs L, Gasowski J, Bulpitt CJ, Clement D, de Leeuw PW, Dobovisek J, Jääskivi M, Leonetti G, O'Brian E, Palatini P, Parati G, Rodicio JL, Vanhanen H, Webster J, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation 2000;102:1139-1144.
80. Hansson L, Lindholm LH, Ekborn T, Dahlöf B, Lanke J, Scherstén B, Wester P-Q, Hedner T, de Faire U, for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-1756.
81. Kjeldsen SE, Hedner T, Syvertsen JO, Lund-Johansen, Hansson L, Lanke J, Lindholm LH, de Faire U, Dahlhöf B, Karlberg BE, for the NORDIL Study Group. Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study. J Hypertens 2002;20:1231-1237.
82. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-1411.
83. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-878.
84. Blaustein MP, Robinson SW, Gottlieb SS, Balke CW, Hamlyn JM. Sex, digitalis, and the sodium pump. Mol Interv 2003;3:68-72.
85. Smith JB, Wade MB, Fineberg NS, Weinberger MH. Influence of race, sex, and blood pressure on erythrocyte sodium transport in humans. Hypertension 1988;12:251-258.
86. (+) pump concentration in patients with chronic heart failure. Muscle Nerve 2001;24:69-76.
87. Furberg CD, Vittinghoff E, Davidson M, Herrington DM, Simon JA, Wenger NK, Hulley S. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation 2002;105:917-922.
88. Merri M, Benhorin J, Alberti M, Locati E, Moss AJ. Electrocardiographic quantitation of ventricular repolarization. Circulation 1989;80:1301-1308.
89. Rautaharju PM, Zhou SH, Wong S, Calhoun HP, Berenson GS, Prineas R, Davignon A. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992;8:690-695.
90. Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Safe 2001;24:575-585.
91. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex differences in risk of torsades de pointes with d,l-sotalol. Circulation 1996;94:2535-2541.
92. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
93. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002;89:1316-1319.
94. Koup JR, Abel RB, Smithers JA, Eldon MA, de Vries TM. Effect of age, gender and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets. Ther Drug Monit 1998;20:73-77.
95. Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000;67:413-418.
96. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001;285:1322-1326.
97. The Cardiac Arrhythmia Suppression Trial Investigators (CAST). Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Eng J Med 1989;321:406-412.
98. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol 2003;91:39-44.
99. Pratt CM, Camm AJ, Cooper W, Friedman PL, MacNeil DJ, Moulton KM, Pitt B, Schwartz PJ, Veltri EP, Waldo AL, for the SWORD Investigators. Mortality in the Survival With ORal D-Sotalol (SWORD) trial: why did patients die? Am J Cardiol 1998;81:869-876.
100. Torp-Pederson C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm JA. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Eng J Med 1999;341:857-865.
101. Massie BM, Fisher SG, Radford M, Deedwania PC, Singh BN, Fletcher RD, Singh SN. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-Stat Investigators. Circulation 1996;93:2128-2134.
102. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R for Grupo de Estudio de la Sobrevida en la Insufficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498.
103. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674.
104. Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infraction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-682.
105. Russo AM, Stamato NJ, Lehmann MH, Hafley GE, Lee KL, Pieper K, Buxton AE, and the MUSTT Investigators. Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial. J Cardiovasc Electrophysiol 2004;15:993-998.
106. Ho PC, Triggs EJ, Bourne DW, Heazlewood VJ. The effect of age and sex on the disposition of acetylsalicyl acid and its metabolites. Br J Clin Pharmacol 1985;19:675-684.
107. Miners JO, Grugrinovich N, Whitehead AG, Robson RA, Birkett DJ. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br J Clin Pharmacol 1986;22:135-142.
108. Spranger M, Aspey BS, Harrison MJ. Sex difference in antithrombotic effect of aspirin. Stroke 1989;20:34-37.
109. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
110. ISIS-2 (Second International Study of Infarct Survival) collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
111. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991;266:521-527.
112. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357:89-95.
113. Ridker PM, Cook NR, Lee I-M, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Eng J Med 2005;352:1293-1304.
114. Sam C, Massaro JM, D'Agostino RB Sr, Levy D, Lambert JW, Wolf PA, Benjamin EJ; Framingham Heart Study. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol 2004;94:947-951.
115. Lenz T, Wilson A. Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. Clin Pharmacokinet 2003;42:909-920.
116. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.
117. Steinhubl SR, Berger PB, Tift Mann J, Fry ETA, deLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002;288:2411-2420.
118. Cannon CP; CAPRIE Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 2002;90:760-762.
119. Bertrand ME, Rupprecht H-J, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624-629.
120. Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996;36:242-246.
121. Cheng H, Rogers JD, Sweany AE, Dobrinska MR, Stein EA, Tate AC, Amin RD, Quan H. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 1992;9:1629-1633.
122. Isaacsohn J, Zinny M, Mazzu A, Lettieri J, Heller AH. Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults. Eur J Clin Pharmacol 2001;56:897-903.
123. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharm 2002;42:1116-1121.
124. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001;40:263-281.
125. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993;6:375-382.
126. FDA. CDER. Report no.: http:www.fda.gov/cder/foi/label2001/207S6lbl.pdf.
127. Shepard DR, Jenid H, Thacker HL. Gender, hyperlipidemia, and coronary artery disease. Compr Ther 2003;29:7-17.
128. Cheung BMY, Lauder IJ, Lau C-P, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57:640-651.
129. Berra K. Women, coronary heart disease, and dyslipidemia: does gender alter detection, evaluation, or therapy? J Cardiovasc Nurs 2000;14:59-78.